FreeMind Group – DTRA Funding Opportunities- Just Issued and Rapidly Approaching!



The Defense Threat Reduction Agency (DTRA) has just updated a very exciting opportunity covering a vast array of topics (see below). The March 14th deadline is rapidly approaching, so start drafting your application today!

The FreeMind Group has extensive experience in assisting clients in completing and winning such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.

To schedule a call with a representative from FreeMind please contact Carla Hamoy at: (617) 648-0340,


HDTRA1-14-CHEM-BIO-BAA, Chemical Biological Technologies Department BAA Synopsis/Solicitation FY2014 – FY2016 Program Build

  • Important deadlines:

March 14, 2014: Phase I proposal receipt deadline (Quad chart/white paper).

April 4, 2014: Phase II proposal receipt invited.

May 7, 2014: Phase II receipt deadline.

June 20, 2014: Notification of selection/non-selection.

November 26, 2014: Estimated first award date.

  • Funding: May request project period of up to 5 years with a budget appropriate for the science proposed.
  • Scope: The Chemical / Biological Technologies Department (CB), in its continuing mission, seeking new and innovative ideas for experimental and theoretical development of technologies to fill DoD requirements for chemical and biological defense.

Topics of Interest:


  • Diagnosis of Antimicrobial Resistance Markers (AMR) and Multidrug Resistance (MDR)
  • Sample to Sequence (S2S)
  • Next Generation Analytic Capabilities for BSV
  • New and Unique Data Sources for BSV
  • BSVE Data Challenge
  • Micro Gas Analyzer Integration


  • Reinvestigating, reformulating, and/or repurposing antimicrobial drugs or leads: Development of improved dosing, drug delivery, or combination therapy to counter biothreats
  • Targeting Mechanisms of Antimicrobial Resistance (AMR) in Bacillus anthracis, Yersinia pestis, Francisella tularensis and Burkholderia pseudomallei
  • Discovery and development of antitoxin against botulinum neurotoxin
  • Q Fever Clinical Immunology and Vaccine Development
  • Closing the Immunity Onset Gap: Urgent Pre-Exposure, and Post-Exposure Prophylaxis with Single Dose, Rapidly Protective Vaccines in Unvaccinated Warfighters
  • Pre-Exposure or Post-Exposure Immuno-Prophylaxis Against Aerosol Exposure to Bacterial or Viral Threat Agents.


HDTRA1-11-16-RDIS, R&D Innovation and Systems Engineering Office Science and Technology New Initiatives – Broad agency announcement

  • Upcoming deadline: Open solicitation which consists of two phases; pre-application followed by an invitation to submit a full application. For the pre-application there is an ongoing deadline.
  • Funding: No cap on the budget. May request a project period of up to 5 years with a budget appropriate for the science proposed.
  • Scope: The directorates and offices within DTRA’s Research and Development (R&D) Enterprise identify, conduct, and deliver innovative science and technology that enable America to combat Weapons of Mass Destruction, all of which are tied to the Strategic Goals and Objectives. Specific capabilities sought in this BAA are in the technology areas of Chemical/Biological, Counter WMD, Radiation/Nuclear, Reachback and Decision Support and Treaty Verification/Compliance.


To schedule a call with a representative from FreeMind please contact Carla Klein at:

(617) 648-0340,


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: